Human medicines European public assessment report (EPAR): Filgrastim Hexal, filgrastim, Neutropenia;Hematopoietic Stem Cell Transplantation;Cancer, Date of authorisation: 06/02/2009, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Opzelura, ruxolitinib, Vitiligo, Date of authorisation: 19/04/2023, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Ziextenzo, pegfilgrastim, Neutropenia, Date of authorisation: 22/11/2018, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Qutenza, capsaicin, Neuralgia, Date of authorisation: 15/05/2009, Revision: 19, Status: Authorised

Website outages and upgrades

Human medicines European public assessment report (EPAR): Levitra, vardenafil, Erectile Dysfunction, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Rilutek, riluzole, Amyotrophic Lateral Sclerosis, Date of authorisation: 10/06/1996, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Clopidogrel Krka, clopidogrel, Peripheral Vascular Diseases;Stroke;Myocardial Infarction, Date of authorisation: 23/09/2009, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Hycamtin, topotecan, Ovarian Neoplasms;Uterine Cervical Neoplasms;Small Cell Lung Carcinoma, Date of authorisation: 12/11/1996, Revision: 39, Status: Authorised

Isotretinoin (oral formulations) : List of nationally authorised medicinal products - PSUSA/00010488/202305